Despite the obvious advantages of conducting thorough assessments in highly controlled laboratory environments, the associated resource burden means that such lengthy assessments are out of the question for daily testing.

The widespread adoption of smartphones and wearables makes monitoring symptoms in real time a credible option using brief measures designed for these devices – but is this acceptable and feasible for patients?

In a Takeda Pharmaceuticals sponsored study, a team of scientists from Cambridge Cognition, Takeda Pharmaceuticals and CTRL Group conducted a six-week investigational study into the acceptability, feasibility and validity of asking patients with major depressive disorder to undertake daily assessments on a wearable device.

In this webinar, scientists on the project will delve into the research findings and share:

  • Lessons learned using digital devices to deliver near-patient assessments
  • Patient adherence and compliance with undertaking daily assessments on a wearable device
  • Correspondence between brief assessments and validated, full-length measures

Featured Speakers

Francesca Cormack

Director of Research & Innovation
Cambridge Cognition

 Francesca is Director of Research and Innovation at Cambridge Cognition. She has extensive experience of statistics, cognitive neuroscience and cognitive test development in a range of clinical populations. Since joining Cambridge Cognition in 2014, Francesca has worked to develop novel cognitive testing methodology to support high-frequency, near patient testing using digital technology, providing researchers and healthcare providers with unique insights into cognitive health. Francesca obtained a PhD in Dementia with Lewy Bodies at Newcastle University, followed by post-doctoral and academic positions at University College London and at the Medical Research Council in Cambridge. She maintains academic collaborations focused on neurological disorders, ageing and dementia.

Maggie McCue

Head, Clinical Research Medical Engagement & Innovation, US Medical
Takeda Pharmaceuticals

 As Head of Clinical Research for Takeda US Medical, Maggie leads Clinical Research across all disease areas (Neuroscience, GI, Rare, Immunology). The focus of her team is to pursue innovative collaborations with a primary emphasis on enhanced patient clinician engagement and advancing scalable healthcare solutions for systems of care, providers and patients through evidence generation and digital solutions.  Maggie has more than 20 years of pharmaceutical research and development experience.  She joined Takeda in 2007 in the CNS therapeutic area and has also worked in General Medicine and Cardiovascular/Metabolic with a specific focus on CV Outcomes.   Prior to Takeda, Maggie spent 10 years at Abbott Laboratories working on Nutritionals, Immunology, Anesthesia and in Metabolic research. Maggie is a Registered Dietitian and completed her MS degree in Nutrition and Clinical Dietetics and is currently completing a PhD in integrated functional nutrition.

Sara Sarkey

VP Neuroscience and Vaccines, US Medical
Takeda Pharmaceuticals

 Sara Sarkey received her PhD in Neuroscience from Loyola University Chicago and is currently the VP, US Medical Head for Neuroscience and Vaccines at Takeda Pharmaceuticals.  Her primary responsibility is to provide medical expertise and leadership for all Medical activities supporting the Neuroscience and Vaccines US portfolio. Takeda Medical seeks to better understand and communicate the real-world effects of Takeda’s medications, but also to partner with other groups within the healthcare system to bring innovative, patient-focused solutions to the treatment of diseases within the Neuroscience portfolio. Prior to joining Takeda Pharmaceuticals in 2006, Sara was in academic research at Loyola University Chicago, focused primarily on the impacts of hormonal regulation on the developing brain.  She has also worked in the fields of Sleep Medicine, Neuroendocrinology, and Psychiatry. Sara currently lives in Arlington Heights, IL with her husband and 2 sons.

NOW AVAILABLE ON-DEMAND

Register now for this webinar